TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
26,027,000
|
22,123,000
|
18,790,000 |
| Financial expenses |
1,305,000
|
1,162,000
|
497,000 |
| Earnings before taxes |
4,407,000
|
2,954,000
|
3,321,000 |
| EBITDA |
9,349,000
|
7,234,000
|
6,087,000 |
| Total assets |
75,444,000
|
74,027,000
|
52,496,000 |
| Current assets |
13,162,000
|
12,671,000
|
11,211,000 |
| Current liabilities |
12,069,000
|
19,095,000
|
14,857,000 |
| Equity capital |
40,286,000
|
33,867,000
|
26,525,000 |
| - share capital |
195,000
|
194,000
|
170,000 |
| Employees (average) |
1,840
|
1,772
|
1,556 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
53.4%
|
45.7%
|
50.5% |
| Turnover per employee |
14,145
|
12,485
|
12,076 |
| Profit as a percentage of turnover |
16.9%
|
13.4%
|
17.7% |
| Return on assets (ROA) |
7.6%
|
5.6%
|
7.3% |
| Current ratio |
109.1%
|
66.4%
|
75.5% |
| Return on equity (ROE) |
10.9%
|
8.7%
|
12.5% |
| Change turnover |
3,904,000
|
3,333,000
|
3,261,000 |
| Change turnover % |
18%
|
18%
|
21% |
| Chg. No. of employees |
68
|
216
|
-3 |
| Chg. No. of employees % |
4%
|
14%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.